Table 1.
Patient characteristicsa
| Nb (%) | |
|---|---|
| Age (yr) | 50 (21 – 68) |
| Male sex | 5 (45%) |
| AIBW (kg) | 64.6 (51.1 – 82.8) |
| Donor relationship | |
| Mother | 2 (18%) |
| Father | 1 (9%) |
| Brother | 2 (18%) |
| Daughter | 3 (27%) |
| Son | 3 (27%) |
| Disease | |
| Non-Hodgkin lymphoma | 5 (45%) |
| Hodgkin lymphoma | 3 (27%) |
| Acute myeloid leukemia/myelodysplastic syndrome (MDS) | 3 (27%) |
| Cytomegalovirus serostatus | |
| Recipient +/Donor − | 5 (45%) |
| Recipient +/Donor + | 4 (36%) |
| Recipient −/Donor − | 1 (9%) |
| Recipient −/Donor + | 1 (9%) |
| Graft source | |
| Peripheral blood stem cells | 8 (73%) |
| Bone marrow | 3 (27%) |
| Post-transplant CYc | |
| One dose (Day +3) | 3 |
| Two doses (Days +3 and +4) | 8 |
a
All patients received the same conditioning regimen prior to HCT;
b
data are presented as median (range) or number (%);
c
all patients received tacrolimus and MMF. One patient’s second dose of post-transplant CY was delayed by 24hr because the patient was not clinically stable.